A Phase Ib, Open-Label Study Evaluating the Safety and Pharmacokinetics of Atezolizumab (Anti-PD-L1 Antibody) Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia
Myeloid and Monocytic Leukemia
What is the purpose of this trial?
This Phase Ib study is designed to evaluate the safety and pharmacokinetics of atezolizumab when given in combination with Hu5F9-F4 to patients with relapsed or refractory (R/R) acute myeloid leukemia (AML).
- Trial withF. Hoffman-La Roche Ltd
- Start Date11/04/2019
- End Date11/18/2021
- Last Updated06/01/2020
- Study HIC#2000025698